Document |
Document Title |
WO/2023/064349A1 |
Pyrrolo[2,3-b]pyridine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,3-b]pyridine compound or analogs thereof, in the treatment of disorders ...
|
WO/2023/064218A1 |
Compounds having activity as inhibitors of TYRO3 are provided. The compounds have Structure (I): (I) or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, wherein L, X, Y, Z, R1, R2a, R2c, R3, p, and n are as...
|
WO/2023/061432A1 |
A pyrimidine tricyclic derivative and a pharmaceutical application thereof. Specifically disclosed are a compound as represented by formula (I), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
|
WO/2023/061294A1 |
Disclosed are a nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and an application thereof. Particularly, disclosed are a compound as represented in general formula (I), a preparation method therefor,...
|
WO/2023/064366A1 |
Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatme...
|
WO/2023/064361A1 |
7H-Pyrrolo[2,3-d]pyrimidine compounds of Formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 7H-pyrrolo[2,3-d]pyrimidine compounds or analogs thereof, in ...
|
WO/2023/064879A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
WO/2023/061434A1 |
The present invention provides a use of a compound represented by formula (A) or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating cancer mediated by EGFR, FGFR2, KIT, ALK and/or ROS1 mutations. The comp...
|
WO/2023/064880A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
WO/2023/061433A1 |
Provided is a compound of formula (A), N-(6-((5-bromo-2-((6-isopropyl-8-methoxy-3-methyl-3,4,5,6-te
trahydrobenzo[b]pyrazolo[4,3-D]aza-9-yl)amino)-pyrimidin-4-y
l)amino)-quinoxaline-5-yl)methanesulfonamide, and a compound of formula (I),...
|
WO/2023/061463A1 |
A pyrimidopyridine compound, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a compound represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a met...
|
WO/2023/059583A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
|
WO/2023/060253A1 |
The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
WO/2023/059605A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
|
WO/2023/059609A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from GSPT1, Cyclin K, RBM23, RBM39, IKZF1, IKZF3, PLK1, CDK4 or CKlalpha which is linked to a moiety that binds to a target protei...
|
WO/2023/059581A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
|
WO/2023/056951A1 |
Disclosed is a novel substituted heterocyclic compound, which can be used as a K-RAS mutation target inhibitor. Specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt, a solvate, a hydrate,...
|
WO/2023/059582A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
|
WO/2023/056039A1 |
Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
|
WO/2023/051635A1 |
Disclosed in the present invention are a fused ring compound, and a preparation method therefor and the use thereof. Provided in the present invention are a fused ring compound as represented by formula I, a tautomer thereof, a stereoiso...
|
WO/2023/053039A1 |
Provided herein are novel compounds having an inhibitory effect on the activation of a STING pathway. The provided compounds are 1,2-diaminobenzimidazole derivatives represented by a compound formula (I) or a pharmaceutically acceptable ...
|
WO/2023/051648A1 |
Provided are a compound as an SHP2 inhibitor, a pharmaceutical composition thereof, and the use thereof in the prevention or treatment of SHP2 activity-mediated diseases.
|
WO/2023/052312A1 |
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including ...
|
WO/2023/048573A1 |
The invention is directed to a hydrogenated Diels-Alder adduct according to formula (I) or a salt thereof wherein X is is H or an aliphatic moiety that is optionally substituted with one or more heteroatom-comprising substitutents such a...
|
WO/2023/046182A1 |
Provided is an application of a pyrido[1,2-a]pyrimidone compound, and specifically involved is an application of a substance X in preparation of a drug. The substance X is a compound represented by formula I, a pharmaceutically acceptabl...
|
WO/2023/049697A1 |
Claimed are compounds of Formula la, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or diso...
|
WO/2023/041066A1 |
Provided are a pyrimidine-containing dihydropyrazolone derivative, a prodrug thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a preparation method therefor and an application thereof. The compound can i...
|
WO/2023/040818A1 |
Disclosed are a RIPK1 inhibitor that inhibits programmed cell necrosis and a preparation method therefor. The disclosed RIK1 inhibitor is represented by general formula I, where X1, X2, X3, X4, X5, Z1, Z2, Z3, L1, L2, L3, R, R1, ring D a...
|
WO/2023/042879A1 |
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
|
WO/2023/040996A1 |
The present application relates to an azaindazole macrocyclic compound and the use thereof. The azainazole macrocyclic compound has a structure of formula I, and has the effect of inhibiting the activity of a plurality of protein kinases...
|
WO/2023/042814A1 |
A compound represented by the general formula is useful as a light-emitting material. R1 to R10 represent a hydrogen atom, a deuterium atom or a substituent, provided that one or two of R1 to R10 represent a cyano group and one to four o...
|
WO/2023/036175A1 |
Disclosed in the present invention are a glutarimide compound, and the use thereof. Specifically disclosed are a compound as represented by formula (VII-0) and a pharmaceutically acceptable salt thereof.
|
WO/2023/039505A1 |
The present disclosure relates compounds of Formula (0): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, a...
|
WO/2023/036156A1 |
The present application relates to a class of DNA-PK selective inhibitors as represented by formula (II), and a preparation method therefor and the use thereof. The use comprises the use of the compound of formula (II) in the preparation...
|
WO/2023/036976A1 |
The present invention relates to a heterocyclic compound of formula (1), which is substituted by at least one cyano group, as well as compositions and devices comprising these compounds, especially organic electroluminescent devices comp...
|
WO/2023/039089A1 |
The invention relates to a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same.
|
WO/2023/039464A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
WO/2023/036993A1 |
The present invention relates to novel trityl-nitroxide radicals as polarizing agents for Dynamic Nuclear Polarization (DNP).
|
WO/2023/034812A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
WO/2023/032940A1 |
The present invention provides a compound which has PDHK inhibitory activity and which is useful for treating or preventing diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia...
|
WO/2023/034811A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
WO/2023/032987A1 |
Provided are: a 6-aminopyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; and a pharmaceutical use thereof. A ...
|
WO/2023/032676A1 |
A compound represented by formula (1). Formula (1): Z1-αa-βb-γc-δd-εe-Z2 [In formula (1), α, β, γ, δ, and ε are units respectively represented by formulae (1α), (1β), (1γ), (1δ), and (1ε), with the proviso that the unit α...
|
WO/2023/029943A1 |
The present invention provides an aromatic heterocyclic compound, a preparation method therefor and an application thereof. The aromatic heterocyclic compound is shown in formula I. The aromatic heterocyclic compound provided in the pres...
|
WO/2023/031399A1 |
The present invention concerns novel specific iron-activable nitrogen-containing derivatives of salinomycin and narasin, their synthesis and their uses in therapy notably for the treatment of cancer.
|
WO/2023/034290A1 |
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...
|
WO/2023/033018A1 |
The present invention provides a compound represented by formula (I). (In the formula, A1, A2, or A3 each independently is a carbon atom or a nitrogen atom, B1, B2, B3, or B4 each independently is a carbon atom or a nitrogen atom, X1 is ...
|
WO/2023/034833A1 |
The present disclosure features compounds (I) and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
WO/2023/025290A1 |
A use of an SHP2 inhibitor for treating tumors containing RAS pathway gene mutations. Specifically, the present invention relates to the use of a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof in the prepa...
|
WO/2023/025116A1 |
The present invention relates to a heterocyclic derivative, a preparation method therefor and the use thereof in medicine. Specifically, the present invention relates to a heterocyclic derivative represented by general formula (I), a pre...
|